Top

Published in:

01-09-2010 | Original Research

Changes in Health Care Costs over Time Following the Cessation of Intimate Partner Violence

Authors: Paul A. Fishman, PhD, Amy E. Bonomi, PhD, MPH, Melissa L. Anderson, MS, Robert J. Reid, MD, PhD, Fred P. Rivara, MD, MPH

Published in: Journal of General Internal Medicine | Issue 9/2010

ABSTRACT

Background

Research has documented greater health care costs attributable to intimate partner violence (IPV) among women during and after exposure. However, no studies have determined whether health care costs for abused women return to baseline levels at some point after their abuse ceases.

Objective

We examine whether health care costs among women exposed to IPV converge with those of non-abused women during a 10-year period following the end of exposure.

Design

Retrospective cohort analysis.

Setting

Group Health Cooperative, a large integrated health care system in the Pacific Northwest.

Participants

Random sample of English-speaking women aged 18–64 enrolled within Group Health and who participated in a telephone survey between June 2003 and August 2005.

Measurements

Total health care costs over an 11-year period from January 1, 1992 to December 31, 2002 were compiled using automated health plan data and comparisons made among women exposed to IPV since age 18 and those who never experienced IPV. IPV included physical, sexual, or psychological violence involving an intimate partner, and was assessed using five questions from the Behavioral Risk Factor Surveillance System.

Results

Relative to women with no IPV history, total health care costs were significantly higher during IPV exposure, costs that were sustained for 3 years following the end of exposure. By the 4th year following the end of exposure to IPV, health care costs among IPV-exposed women were similar to non-abused women, and this pattern held for the remainder of the 10-year study period.

Conclusions

Policy makers should consider the ongoing needs of victims following abuse exposure. Interventions to reduce the prevalence of IPV or to mitigate the impact of IPV have the potential to reduce the rate of growth of health care costs.

Bonomi AE, Anderson ML, Rivara FP, Thompson RS. Health care utilization and costs associated with physical and non-physical intimate partner violence. Health Serv Res. 2009;44(3):1052–1067.CrossRefPubMed

Rivara FP, Anderson ML, Fishman P, et al. Healthcare utilization and costs for women with a history of intimate partner violence. Am J Prev Med. 2007;32(2):89–96.CrossRefPubMed

Arias I, Corso P. Average cost per person victimized by an intimate partner of the opposite gender: A comparison of men and women. Violence Vict. 2005;20:379–391.CrossRefPubMed

Snow Jones A, Dienemann J, Schollenberger J, et al. Long-term costs of intimate partner violence in a sample of female HMO enrollees. Womens Health Issues. 2006;16(5):252–261.CrossRef

Coker AL, Reeder CE, Fadden MK, Smith PH. Physical partner violence and Medicaid utilization and expenditures. Public Health Rep. 2004;119:557–567.CrossRefPubMed

Max W, Rice DP, Finkelstein E, Bardwell RA, Leadbetter S. The economic toll of intimate partner violence against women in the United States. Violence Vict. 2004;19(3):259–272.CrossRefPubMed

Thompson RS, Bonomi AE, Anderson M, et al. Intimate partner violence: prevalence, types, and chronicity in adult women. Am J Prev Med. 2006;30:447–457.CrossRefPubMed

Bonomi AE, Thompson RS, Anderson ML, et al. Intimate partner violence and women’s physical, mental, and social functioning. Am J Prev Med. 2006;30:458–466.CrossRefPubMed

Vest JR, Catlin TK, Chen JJ, Brownson RC. Multistate analysis of factors associated with intimate partner violence. Am J Prev Med. 2002;22:156–164.CrossRefPubMed

10.

Verhoek-Oftedahl W, Pearlman DN, Coutu Babcock J. Improving surveillance of intimate partner violence by use of multiple data sources. Am J Prev Med. 2000;19(4):308–315.CrossRefPubMed

11.

Lemon SC, Verhoek-Oftedahl W, Donnelly EF. Preventive health care use, smoking and alcohol use among Rhode Island women experiencing intimate partner violence. J Women's Health Gend-Based Med. 2002;11(6):555–562.CrossRef

12.

Breiding MJ, Black MC, Ryan GW. Chronic disease and health risk behaviors associated with intimate partner violence—18 US states/territories, 2005. Ann Epidemiol. 2008;18(7):538–544.CrossRefPubMed

13.

Saltzman LE, Fanslow JL, McMahon PM. Intimate partner violence surveillance uniform definitions and recommended data elements, 1.0 ed. Atlanta GA: National Center for Injury Prevention and Control, Centers for Disease Control and Prevention; 1999.

14.

Smith PH, Earp JA, DeVellis R. Measuring battering: development of the Women’s Experience of Battering (WEB) Scale. Women Health. 1995;1:273–288. 26.

15.

Buehler J, Dixon B, Toomey K. Lifetime and annual incidence of intimate partner violence and resulting injuries—Georgia, 1995. MMWR Morb Mortal Wkly Rep. 1998;47:849–853.

16.

Bensley L, Macdonald S, Van Eenwyk J. Wyncoop Simmons K, Ruggles D. Prevalence of intimate partner violence and injuries—Washington, 1998. MMWR Morb Mortal Wkly Rep. 2000;59:589–592.

17.

Hathaway J, Silverman J, Aynalem G, Mucci L, Brooks D. Use of medical care, police assistance, and restraining orders by women reporting intimate partner violence—Massachusetts, 1996–1997. MMWR Morb Mortal Wkly Rep. 2000;49:485–488.

18.

Fishman PA, Wagner EH. Managed care data and public health: the Experience of Group Health Cooperative of Puget Sound. Annu Rev Public Health. 1998;19:477–491.CrossRefPubMed

19.

U.S. Bureau of Labor Statistics. Databases, Tables and Calculators by Subject. Available at http://www.bls.gov/data. Accessed March 30, 2010.

20.

Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005;24(3):465–488.CrossRefPubMed

21.

Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461–494.CrossRefPubMed

22.

Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Public Health. 1993;14:43–68.CrossRefPubMed

23.

Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29(5):452–472.CrossRefPubMed

24.

Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29(5):452–472. 2.CrossRefPubMed

25.

The Johns Hopkins Adjusted Clinical Group (ACG) Case-mix Adjustment System [computer program]. Version 6. Baltimore MD: The Johns Hopkins University; 2003.

26.

Campbell J, Jones AS, Dienemann J, et al. Intimate partner violence and physical health consequences. Arch Intern Med. 2002;162:1157–1163.CrossRefPubMed

27.

Brokaw J, Fullerton-Gleason L, Olson L, Crandall C, McLaughlin S, Sklar D. Health status and intimate partner violence: a cross-sectional study. Ann Emerg Med. 2002;39:31–38.CrossRefPubMed

28.

Holder HD. Cost benefits of substance abuse treatment: an overview of results from alcohol and drug abuse. J Ment Health Policy Econ. 1998;1:23–29.CrossRefPubMed

29.

Jackson CA, Manning WG Jr, Wells KB. Impact of prior and current alcohol use on use of services by patients with depression and chronic medical illnesses. Health Serv Res. 1995;30:687–705. 48.PubMed

30.

Holder HD, Cisler RA, Longabaugh R, Stout RL, Treno AJ, Zweben A. Alcoholism treatment and medical care costs from Project MATCH. Addiction. 2000;95:999–1013. 49.CrossRefPubMed

31.

Kane RL, Wall M, Potthoff S, McAlpine D. Isolating the effect of alcoholism treatment on medical care use. J Stud Alcohol. 2004;65:758–765. 50.PubMed

32.

Parthasarathy S, Weisner CM. Five-year trajectories of health care utilization and cost in a drug and alcohol treatment sample. Drug Alcohol Depend. 2005;80:231–240.CrossRefPubMed

33.

Nicolaidis C, Touhouliotis V. Addressing intimate partner violence in primary care: lessons from chronic illness management. Violence Vict. 2006;21(1):101–115.CrossRefPubMed

Title: Changes in Health Care Costs over Time Following the Cessation of Intimate Partner Violence
Authors: Paul A. Fishman, PhD
Amy E. Bonomi, PhD, MPH
Melissa L. Anderson, MS
Robert J. Reid, MD, PhD
Fred P. Rivara, MD, MPH
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Journal of General Internal Medicine / Issue 9/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-010-1359-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ABSTRACT

Background

Objective

Design

Setting

Participants

Measurements

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2010

Using N-of-1 Trials to Improve Patient Management and Save Costs

Decreased Length of Stay and Cumulative Hospitalized Days Despite Increased Patient Admissions and Readmissions in an Area of Urban Poverty

Hypoglycemia is More Common Among Type 2 Diabetes Patients with Limited Health Literacy: The Diabetes Study of Northern California (DISTANCE)

Patients’ Evaluations of Health Care Providers in the Era of Social Networking: An Analysis of Physician-Rating Websites

Methadone Deaths in Pain and Addiction Populations

An Uncommon Cause of Headache

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials